Today: October 22, 2016, 5:35 am

United States brand name pharmaceutical manufacturing market: $176.7 billion industry by 2018
Brand Name Pharmaceutical Manufacturing in the US - Industry Market Research Report - a new market research report on 2014-04-18 21:41:01
While the United States brand name pharmaceutical manufacturing market may have proven relatively resilient to the recession, competition from generic drugs has hampered its performance over the past five years. Industry revenue is expected to fall at an average annual rate of 2.3% to $160.6 billion, including a 0.7% drop in 2013.

Historically, sales have been bolstered by favorable demographic trends and the use of medication as a significant component of healthcare in the United States; however, the industry is facing mounting competition from generic pharmaceuticals. Since 2010, many major products, such as Lipitor, have lost patent protection. Because generics are sold at a significant discount to brand-name drugs, companies came under pricing pressure from downstream customers, causing operating profit to decrease.

Players in the industry have tried to adapt to expiring patents by investing more in biological drugs. The Patient Protection and Affordable Care Act of 2010 introduced a method for the US Food and Drug Administration to approve generic biologics, but also initiated a 12-year patent period on these types of drugs. While this legislation increases the threat from generic pharmaceutical manufacturers in this segment of the industry, it also paves a clearer path for operators to manufacture generic biologic drugs.

Consequently, biologics will continue to play an important role in shaping this industry´s future. Healthcare reform is also expected to boost sales as more individuals gain prescription drug coverage in 2014. IBISWorld forecasts revenue to reach $176.7 billion in 2018, representing an estimated average annual increase of 1.9% over the next five-year period.

Nonetheless, the average operating profit margin is expected to decrease slightly to 19.6% of revenue as a result of the industry´s agreement to pay out $84.8 billion in taxes and discounts over the next 10 years to 2021 as part of the 2010 healthcare reform bill. To maintain profitability, industry operators are anticipated to continue consolidating and reducing costs, mainly through reductions in employment and research and development expenditure. During the five years to 2018, employment is projected to decrease 0.1% per year on average to 181,619 individuals.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 542 Words
Related Articles
More From Finance
P2P lending platform Monexo partners with IDBI-Trusteeship [..]
For Immediate Release: 2nd September 2016 MUKESH BUBNA, CEO Monexo Fintech Pvt Limited P2P [..]
Day Trade to Win New September Class [..]
Sold Out? New Class Added – On September 6, 2016, is launching a brand new eight-week trading boot camp [..]
FTM (Forget The Market) Reopens 3 Shares [..]
Port Vila, Vanuatu, 28th July 2016 - Investment firm FTM today announced the reopening of three separate share options, projected [..]
Ex-Citibanker Launching Online P2P marketplace in India [..]
A study conducted by World Bank shows that MSMEs in India face an estimated credit gap of INR 20.9 trillion [..]
New Frontier Portfolios Top Morningstar Rankings
New Frontier’s global strategic portfolios topped the Global Balanced Strategic/All-Inclusive category of the latest Morningstar ETF [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.